Technology | Cardiovascular Surgery | February 01, 2019

SherpaPak Cardiac Transport System Cleared for Pediatric and Small Donor Hearts

System will be shipped with heart connectors covering most aortic diameters beginning Q1 2019

SherpaPak Cardiac Transport System Cleared for Pediatric and Small Donor Hearts

February 1, 2019 — Paragonix Technologies Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) for a design enhancement allowing for the use of the Paragonix SherpaPak Cardiac Transport System (CTS) with small and pediatric donor hearts. Starting in Q1 2019, the system will now be shipped with heart connectors covering most aortic diameters, permitting the anchoring of various size hearts including small pediatric hearts to its proprietary suspension system for improved donor heart transport.

The system has been used by heart transplant centers in both the United States and in Europe. The device is currently marketed in the United Kingdom, France, Spain, Italy, Germany, Austria and Slovak Republic in Europe.

Cardiac transplantation is considered the gold standard therapy for patients in end-stage heart failure. With over 6.5 million Americans currently diagnosed with heart failure, 10 percent of which are diagnosed with end-stage heart failure, there is a persistent need to provide end-stage heart failure support to this expanding population. Estimates of the prevalence of symptomatic HF in the general European population are similar to those in the United States. In 2017, over 2,000 donor hearts were transplanted in Europe.

The annual U.S. economic burden of treating heart failure exceeds $34.4 billion, over 50 percent of which is due to the cost of hospitalization. The financial demands associated with transplantation are considerable. The estimated first year costs for heart transplant are $997,700, and subsequent annual costs can easily exceed $30,000. In the U.S., around 30,000 people die annually from end-stage heart disease. As of February 2018, 3,990 patients in the U.S. were on the waiting list for a heart transplant and close to 4,000 patients in Europe are on the waiting list for a heart transplant every year. In 2017, 3,244 patients in the U.S. and over 2,000 European patients received a live-saving heart transplant. These data, however, only seem to represent the tip of the iceberg. Assuming that up to 157,000 people with end-stage heart failure are candidates for transplantation, maximization of donor organ utilization has enormous potential in cardiac transplantation.

The Paragonix SherpaPak Cardiac Transport System (CTS) safeguards hearts during the journey from donor to recipient patient. The device incorporates cold preservation techniques in a novel suspension system to provide physical and thermal protection.

For more information: www.paragonixtechnologies.com


Related Content

News | Cardiovascular Surgery

June 13, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest ...

Home June 13, 2024
Home
News | Cardiovascular Surgery

June 3, 2024 — Morristown Medical Center’s Gagnon Cardiovascular Institute’s structural heart program recently reported ...

Home June 03, 2024
Home
News | Cardiovascular Surgery

May 16, 2024 — A recent publication in the American Heart Association Circulation highlights a comprehensive ...

Home May 16, 2024
Home
News | Cardiovascular Surgery

April 30, 2024 — The expanding use of transcatheter technologies has changed the landscape in the treatment of valvular ...

Home April 30, 2024
Home
News | Cardiovascular Surgery

April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest ...

Home April 23, 2024
Home
News | Cardiovascular Surgery

March 20, 2024 — PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable ...

Home March 20, 2024
Home
News | Cardiovascular Surgery

February 26, 2024 — Hackensack Meridian Jersey Shore University Medical Center and Hackensack University Medical Center ...

Home February 26, 2024
Home
Feature | Cardiovascular Surgery

The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first ...

Home February 23, 2024
Home
News | Cardiovascular Surgery

January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under ...

Home January 29, 2024
Home
News | Cardiovascular Surgery

January 11, 2024 — Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication ...

Home January 11, 2024
Home
Subscribe Now